Home Featured Page 277

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

9 Women of Color Creating A More Inclusive Psychedelic Movement

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

Lobe Sciences Becomes Enterprise Member of NFL Alumni Association

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

ICSS for Assessing the Abuse Potential of Psychedelics

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

PTSF53 – Psychedelics and Creativity, with Laura Dawn

COMPASS Pathways appoints Wayne J Riley MD to its Board of...

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

9 Women of Color Creating A More Inclusive Psychedelic Movement

Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement

Lobe Sciences Becomes Enterprise Member of NFL Alumni Association

MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital...

Nova Mentis Establishes Serotonin Research Centre

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY